Sign Up Today and Learn More About Neurona Therapeutics Stock
Invest in or calculate the value of your shares in Neurona Therapeutics or other pre-IPO companies through EquityZen's platform.

Neurona Therapeutics Stock (NEOT)
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
About Neurona Therapeutics Stock
Founded
2008
Headquarters
San Francisco, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Neurona Therapeutics Press Mentions
Stay in the know about the latest news on Neurona Therapeutics
Neutron Therapeutics and Helsinki University Hospital Treat First Head and Neck Cancer Patients Using Accelerator-Based Boron Neutron Capture Therapy
prnewswire • May 17, 2025
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
morningstar • Apr 28, 2025
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
globenewswire • Apr 28, 2025
The Brain Cleaning of Sleep Now Achieved During Wakefulness
prnewswire • Apr 14, 2025
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
businesswire • Apr 07, 2025
Neurona Therapeutics Management
Leadership team at Neurona Therapeutics
Chief Financial Officer / Chief Business Officer
James Stutz
Board Member
Erica Whittaker

Join now and verify your accreditation status to gain access to:
- Neurona Therapeutics Current Valuation
- Neurona Therapeutics Stock Price
- Neurona Therapeutics Management
- Available deals in Neurona Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Neurona Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Neurona Therapeutics Revenue and Financials
- Neurona Therapeutics Highlights
- Neurona Therapeutics Business Model
- Neurona Therapeutics Risk Factors
- Neurona Therapeutics Research Report from SACRA Research
Trading Neurona Therapeutics Stock
How to invest in Neurona Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Neurona Therapeutics through EquityZen funds. These investments are made available by existing Neurona Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Neurona Therapeutics stock?
Shareholders can sell their Neurona Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."